Abiopharma

🔍 Vargeese Chandra (Executive)

Company: Wave Life Sciences Ltd. (WVE)

Report Date: 2026-02-05

Detailed Transactions and Holdings:

• Acquired 45,625 shares of Ordinary Shares (Direct)
  Date: 2026-02-05 | Code: A | equity_swap_involved: false | shares_owned_after: 411,474.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 3,228 shares of Ordinary Shares at $13.45 per share (Direct)
  Date: 2026-02-09 | Code: S | equity_swap_involved: false | shares_owned_after: 408,246.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 273,750 shares of Share Option (right to buy) at $12.75 per share (Derivative)
  Date: 2026-02-05 | Code: A | Expires: 2036-02-05 | equity_swap_involved: false | shares_owned_after: 273,750.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.
• F2: Includes 3,162 ordinary shares acquired on July 15, 2025, and January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan.
• F3: On February 9, 2026, the reporting person sold 3,228 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
• F4: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.
• REMARKS: Chief Technology Officer, Head of Platform Discovery Sciences